What regulatory challenges are facing the life sciences sector?
Charleen O’Keeffe, William Fry. Image: Luke Maxwell/Siliconrepublic.com
William Fry’s Charleen O’Keeffe discusses some of the regulatory trends and challenges she sees coming down the line.
The last year has seen a massive acceleration when it comes to digital transformation and the life sciences industry is not immune.
From game-changing technologies within the healthcare sector to the increased demand for telemedicine, there are plenty of ways digitisation is improving the industry as a whole.
Charleen O’Keeffe, a partner in William Fry’s life sciences group, spoke to Siliconrepublic.com about some of these trends in more detail. She said along with digitisation, there is also a move towards non-pharmacological intervention, the use of devices to screen for diseases and changes to the medicines themselves.